Global Recombinant Human Granulocyte Colony-Stimulating Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Recombinant Human Granulocyte Colony-Stimulating Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Granulocyte-colony stimulating factor (G-CSF or GCSF), also known as colony-stimulating factor 3 (CSF 3), is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.
Functionally, it is a cytokine and hormone, a type of colony-stimulating factor, and is produced by a number of different tissues. The pharmaceutical analogs of naturally occurring G-CSF are called filgrastim and lenograstim.
G-CSF also stimulates the survival, proliferation, differentiation, and function of neutrophil precursors and mature neutrophils.
Recombinant Human Granulocyte Colony-Stimulating report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Recombinant Human Granulocyte Colony-Stimulating market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Chemotherapy Induced Neutropenia and Before Blood Donation are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Recombinant Human Granulocyte Colony-Stimulating industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Recombinant Human Granulocyte Colony-Stimulating key manufacturers include Amgen, Qilu Pharmaceutical, Shijiazhuang Pharmaceutical, Kyowa Hakko Kirin, Gensci, Amoytop Biotech, Hangzhou Jiuyuan, Huaxin and Triprime, etc. Amgen, Qilu Pharmaceutical, Shijiazhuang Pharmaceutical are top 3 players and held % sales share in total in 2022.
Recombinant Human Granulocyte Colony-Stimulating can be divided into Lenograstim (Granocyte), Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim) and Others,, etc. Lenograstim (Granocyte) is the mainstream product in the market, accounting for % sales share globally in 2022.
Recombinant Human Granulocyte Colony-Stimulating is widely used in various fields, such as Chemotherapy Induced Neutropenia, Before Blood Donation, Stem Cell Transplants and Others, etc. Chemotherapy Induced Neutropenia provides greatest supports to the Recombinant Human Granulocyte Colony-Stimulating industry development. In 2022, global % sales of Recombinant Human Granulocyte Colony-Stimulating went into Chemotherapy Induced Neutropenia filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Human Granulocyte Colony-Stimulating market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Amgen
Qilu Pharmaceutical
Shijiazhuang Pharmaceutical
Kyowa Hakko Kirin
Gensci
Amoytop Biotech
Hangzhou Jiuyuan
Huaxin
Triprime
Sinovac
Zhaoke
Kawin
Segment by Type
Lenograstim (Granocyte)
Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)
Others
Chemotherapy Induced Neutropenia
Before Blood Donation
Stem Cell Transplants
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Recombinant Human Granulocyte Colony-Stimulating market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Recombinant Human Granulocyte Colony-Stimulating, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Recombinant Human Granulocyte Colony-Stimulating industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Recombinant Human Granulocyte Colony-Stimulating in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Recombinant Human Granulocyte Colony-Stimulating introduction, etc. Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Recombinant Human Granulocyte Colony-Stimulating market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Functionally, it is a cytokine and hormone, a type of colony-stimulating factor, and is produced by a number of different tissues. The pharmaceutical analogs of naturally occurring G-CSF are called filgrastim and lenograstim.
G-CSF also stimulates the survival, proliferation, differentiation, and function of neutrophil precursors and mature neutrophils.
Recombinant Human Granulocyte Colony-Stimulating report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Recombinant Human Granulocyte Colony-Stimulating market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Chemotherapy Induced Neutropenia and Before Blood Donation are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Recombinant Human Granulocyte Colony-Stimulating industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Recombinant Human Granulocyte Colony-Stimulating key manufacturers include Amgen, Qilu Pharmaceutical, Shijiazhuang Pharmaceutical, Kyowa Hakko Kirin, Gensci, Amoytop Biotech, Hangzhou Jiuyuan, Huaxin and Triprime, etc. Amgen, Qilu Pharmaceutical, Shijiazhuang Pharmaceutical are top 3 players and held % sales share in total in 2022.
Recombinant Human Granulocyte Colony-Stimulating can be divided into Lenograstim (Granocyte), Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim) and Others,, etc. Lenograstim (Granocyte) is the mainstream product in the market, accounting for % sales share globally in 2022.
Recombinant Human Granulocyte Colony-Stimulating is widely used in various fields, such as Chemotherapy Induced Neutropenia, Before Blood Donation, Stem Cell Transplants and Others, etc. Chemotherapy Induced Neutropenia provides greatest supports to the Recombinant Human Granulocyte Colony-Stimulating industry development. In 2022, global % sales of Recombinant Human Granulocyte Colony-Stimulating went into Chemotherapy Induced Neutropenia filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Human Granulocyte Colony-Stimulating market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Amgen
Qilu Pharmaceutical
Shijiazhuang Pharmaceutical
Kyowa Hakko Kirin
Gensci
Amoytop Biotech
Hangzhou Jiuyuan
Huaxin
Triprime
Sinovac
Zhaoke
Kawin
Segment by Type
Lenograstim (Granocyte)
Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)
Others
Segment by Application
Chemotherapy Induced Neutropenia
Before Blood Donation
Stem Cell Transplants
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Recombinant Human Granulocyte Colony-Stimulating market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Recombinant Human Granulocyte Colony-Stimulating, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Recombinant Human Granulocyte Colony-Stimulating industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Recombinant Human Granulocyte Colony-Stimulating in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Recombinant Human Granulocyte Colony-Stimulating introduction, etc. Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Recombinant Human Granulocyte Colony-Stimulating market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices